Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

Last 28 March 2025, the European Commission decided not to renew the conditional marketing authorisation for Translarna (ataluren) in Duchenne’s disease due to lack of efficacy after 11 years in the ...

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of ...

Good morning, and welcome to the Dyne Therapeutics' call to review the top line clinical results from the DELIVER trial in Duchenne muscular dystrophy. Today's call will be hosted by John Cox, ...

Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the “best ever” for ...

There is no cure for DMD, but treatments can slow the progression of the disease and help improve quality of life. Duchenne muscular dystrophy (DMD) is a chronic condition that causes a gradual loss ...

Duchenne muscular dystrophy (DMD) treatment Exondys 51 (eteplirsen) may help protect the heart as well as muscles used for movement, a study found. The treatment slowed heart function decline, raising ...

DYNE-251 received FDA breakthrough therapy designation for DMD, showing promising clinical evidence of improvement over existing therapies. The DELIVER trial demonstrated sustained functional ...

Chugai Pharmaceutical Co., Ltd. announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for Elevidys Intravenous Infusion [generic name: delandistrogene ...

Tevard to present preclinical data showing tRNA restored full-length dystrophin accompanied by functional muscle improvement in an animal model of DMD. The model targeted nonsense mutations, which are ...

April 29, 2025 -- Boston, MA -- Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, will present preclinical ...